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A B S T R A C T
Purpose
Detection of speciﬁc molecular alterations in tumors guides the selection of effective targeted
treatment of patients with several types of cancer. These molecular alterations may occur in other
tumor types for which the efﬁcacy of targeted therapy remains unclear. The MyPathway study
evaluates the efﬁcacy and safety of selected targeted therapies in tumor types that harbor relevant
genetic alterations but are outside of current labeling for these treatments.
Methods
MyPathway (ClinicalTrials.gov identiﬁer: NCT02091141) is a multicenter, nonrandomized, phase IIa
multiple basket study. Patients with advanced refractory solid tumors harboring molecular alter-
ations in human epidermal growth factor receptor-2, epidermal growth factor receptor, v-raf murine
sarcoma viral oncogene homolog B1, or the Hedgehog pathway are treated with pertuzumab plus
trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. The primary end point is investigator-
assessed objective response rate within each tumor-pathway cohort.
Results
Between April 1, 2014 and November 1, 2016, 251 patients with 35 different tumor types received
study treatment. The efﬁcacy population contains 230 treated patients who were evaluated for
response or discontinued treatment before evaluation. Fifty-two patients (23%) with 14 different
tumor types had objective responses (complete, n = 4; partial, n = 48). Tumor-pathway cohorts with
notable objective response rates included human epidermal growth factor receptor-2–ampliﬁed/
overexpressing colorectal (38% [14 of 37]; 95% CI, 23% to 55%) and v-raf murine sarcoma viral
oncogene homolog B1 V600-mutated non–small-cell lung cancer (43% [six of 14]; 95% CI, 18% to
71%).
Conclusion
The four currently approved targeted therapy regimens in the MyPathway study produced
meaningful responses when administered without chemotherapy in several refractory solid tumor
types not currently labeled for these agents.
J Clin Oncol 36:536-542. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Molecular proﬁling is routinely used to guide the
selection of targeted therapies for the treatment of
patients with lung, breast, colon, and other types of
cancer. When used in molecularly identiﬁed patients
with indicated tumor types, agents targeting human
epidermal growth factor receptor-2 (HER2),1 epi-
dermal growth factor receptor (EGFR),2 v-raf murine
sarcoma viral oncogene homolog B1 (BRAF),3 and
the Hedgehog pathway4 have been among the most
effective therapies introduced during the last 20 years.
Molecular alterations in these genes and
pathways also occur in a variety of nonindicated
tumor types. The low incidence of the targeted
molecular alterations in these tumor types
(usually , 5%) has made it difﬁcult to recruit
sufﬁcient numbers of patients into traditional
drug development studies, although activity has
been documented in anecdotal reports.5-12
Basket studies provide the opportunity to
evaluate the efﬁcacy of targeted therapies in patient
populations deﬁned by the presence of speciﬁc
molecular tumor abnormalities, rather than by
primary site or tumor histology.13,14 Results of
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several small basket studies have recently been reported. In one such
study (ClinicalTrials.gov identiﬁer: NCT01524978), treatment with
vemurafenib produced responses in 24 of 95 patients (25%) with
BRAF V600-mutated tumor types other than melanoma and co-
lorectal cancer.15 Such data suggest that certain molecular alterations
are important in determining the response to targeted treatment,
independent of tumor type.16 However, multiple variables inﬂuence
the efﬁcacy of targeted therapy, including the biology and relevance
of the target, themechanism of target inhibition, the tumor type, the
presence of other molecular alterations, and the therapy selected.
MyPathway is an ongoing, multicenter, phase IIa study that
combines multiple basket studies under an adaptable master
protocol. The objective of the study is to evaluate the efﬁcacy of
treatments targeting molecular alterations in HER2 (pertuzumab
plus trastuzumab), BRAF (vemurafenib), Hedgehog pathway
(vismodegib), or EGFR (erlotinib) in patients with tumor types
outside of current labeling for these treatment regimens. In this
report, we summarize the efﬁcacy results in the ﬁrst 230 treated
patients who were efﬁcacy evaluable.
METHODS
Patients
Eligible patients are required to have refractory, metastatic solid tumors
containing targetable, pathway-activating, molecular alterations in HER2,
EGFR, BRAF, or the Hedgehog pathway. Molecular proﬁling was not con-
ducted as part of this study; rather, eligible patients were required to have
previous proﬁling demonstrating one of the target alterations. Molecular
testing by various local Clinical Laboratory Improvement Amendments
(CLIA)-approved laboratories was acceptable in this study. Molecular proﬁling
must have been performed on tissue obtained at themost recent tumor biopsy.
Additional eligibility requirements include measurable or evaluable
lesions17 and an Eastern Cooperative Oncology Group performance status
score of 0, 1, or 2. Patients with tumor types for which the study treatments
are approved or in active development are not eligible. Speciﬁc tumor
mutations with evidence suggesting inactivity of the study drugs are also
ineligible. All patients also need to fulﬁll additional eligibility criteria
pertinent to the speciﬁc therapeutic agents (Data Supplement).
Molecular alterations eligible for MyPathway as well as required
testing methods are detailed in Table 1. Tumors with HER2 ampliﬁcation,
overexpression, and/or activating mutations were eligible. For EGFR and
BRAF, known or putative activating mutations were required. Eligible
Hedgehog pathway alterations included gain-of-function mutations of
Smoothened (SMO) or loss-of-function mutations of Patched Homolog-1
(PTCH-1). Unusual mutations considered possible activating mutations
for any of the pathways (or loss of function mutations for PTCH-1) were
permitted if previously reported in at least two unique specimens in the
Catalogue of Somatic Mutations in Cancer database.6
The above protocol-speciﬁed molecular alterations were identiﬁed
through local CLIA-approved laboratory reports and reviewed by the study
medical monitor for eligibility. For unusual molecular alterations, the
medical monitor consulted appropriate members of the MyPathway
Steering Committee regarding eligibility. Scanned laboratory reports are
kept in a separate database from clinical trial data.
Trial Design
MyPathway (ClinicalTrials.gov identiﬁer: NCT02091141) is a multi-
center, nonrandomized, open-label, multiple basket phase IIa trial (Fig 1).
Eligible patients are assigned to a speciﬁc treatment cohort on the basis of the
presence of a relevant target molecular alteration in their tumor biopsy.19
Patients with two or more study-eligible alterations may be treated for the
alteration that the investigator considers most clinically relevant and may
subsequently enter a different treatment cohort if they remain eligible.
Dosages of study treatments are in accordance with the United States
package inserts for each product20-24 and are administered without sys-
temic chemotherapy. Patients with HER2 molecular alterations are treated
with intravenous pertuzumab (840 mg loading dose followed by 420 mg
every 3 weeks) plus intravenous trastuzumab (8 mg/kg loading dose
followed by 6 mg/kg every 3 weeks). Patients with EGFR-activating mu-
tations are treated with erlotinib (150 mg orally once daily). Patients with
BRAFmutations are administered vemurafenib (960mg orally twice daily),
and those with Hedgehog pathway alterations receive vismodegib (150 mg
orally once daily). Patients receive treatment of two cycles (6 weeks for
pertuzumab plus trastuzumab; 8 weeks for all oral agents) and are then
evaluated for response. Patients with objective response or stable disease
(SD) continue therapy, with repeat evaluations every two cycles for the ﬁrst
24 weeks, followed by evaluations every 12 weeks, until tumor progression,
unacceptable toxicity, or other discontinuation criteria are met.
Trial Oversight
The MyPathway protocol was approved by the institutional review
board/ethics committee at each trial center. Written informed consent is
obtained before any screening procedures. Genentech and the Sarah
Cannon Research Institute designed the trial in collaboration with the
MyPathway Steering Committee. The MyPathway Steering Committee
meets three times per year, and when necessary, to review safety and
efﬁcacy data and preplanned futility analyses. All authors have access to the
data and vouch for the accuracy and completeness of the analyses reported
and for the ﬁdelity of the trial to the protocol.
Study End Points
The primary efﬁcacy end point for MyPathway is the objective re-
sponse rate (ORR). Responses are assessed by the investigator according to
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.17
Conﬁrmation of response (per RECIST) is not required. Secondary efﬁcacy
end points include duration of response (DOR), progression-free survival,
and 1-year overall survival. DOR is measured from the date of ﬁrst docu-
mentation of an objective response to the date of tumor progression/death or
Table 1. Eligible Molecular Alterations and Testing Methods
Target
Pathway
Molecular
Alteration
Testing
Method
Result Required
for Eligibility
HER2 Overexpression or IHC 3+ staining
Ampliﬁcation or FISH/CISH HER2/CEP17 ratio . 2.0 or
Copy number . 6
NGS Copy number increased
Mutation NGS Activating mutation*
BRAF Mutation NGS V600E mutation† or
Other BRAF mutation
EGFR Mutation NGS Activating mutation‡
Hedgehog Mutation NGS SMO activating mutation§ or
PTCH-1 loss-of-function
mutation||
Abbreviations: CEP17, centromeric probe for chromosome 17; IHC, immuno-
histochemistry; FISH/CISH, ﬂuorescent or chromogenic in situ hybridization;
HER2, human epidermal growth factor receptor-2; NGS, next-generation se-
quencing; SMO, Smoothened; PTCH-1, patched homolog-1.
*Includes exon 20 insertions, deletions around amino acids 755 to 759, and
several nonsynonymous amino acid substitutions.
†Patients with coexisting KRAS mutations were excluded.
‡Includes nonsynonymous exon 18 or exon 21mutations, or exon 19 deletions;
exon 20 mutations not eligible.18
§W535L or other nonsynonymous mutations.
||Indels with 6 5 amino acids from previously described indels resulting in
frameshifts; nonsense mutations 6 5 amino acids from previously reported
nonsynonymous mutations.
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the last tumor assessment (if there was no progressive disease or death).
Efﬁcacy end points are evaluated separately for each tumor-pathway cohort, as
deﬁned by speciﬁc tumor type and molecular alteration.
Statistical Analysis
Analyses of ORR were performed in the efﬁcacy analysis population,
which included patientswithmeasurable diseasewhowere treated and had been
evaluated for tumor response or who had been discontinued from treatment for
any reason before the ﬁrst response evaluation. Analyses of the DOR include the
efﬁcacy analysis patients who had objective responses. The data cutoff date for
this interim efﬁcacy analysis population was November 1, 2016.
ORRs were calculated for each tumor-pathway cohort. The 95% CIs
of ORR were constructed using exact binomial distribution (Clopper-
Pearson estimation method). The Kaplan-Meier approach was used to
estimate median DORs and their 95% CIs and median follow-up duration.
For each tumor-pathway cohort, Simon’s two-stage design was used
to make a preliminary assessment of treatment activity. For treatment-
resistant tumor types (eg, non–small-cell lung cancer [NSCLC] and bil-
iary), at least one response in the ﬁrst 12 patients was required for cohort
expansion; otherwise, the cohort was closed for futility (testing hypothesis:
ORR, 5% v 20% at 10% one-sided type I error, 80% power). The
MyPathway Steering Committee was consulted to determine treatment-
resistant tumor types. For less-resistant tumor types (eg, colorectal, ovary),
at least two responses in the ﬁrst 13 patients were required for cohort
expansion (testing hypothesis: ORR, 10% v 25% at 10% one-sided type I
error, 80% power). If preliminary activity was demonstrated, accrual to the
cohort continued to a maximum of 75 patients.
The initial study protocol did not include formal plans for separate
analyses of cohorts with HER2 ampliﬁcation/overexpression and HER2
mutation. However, apparent differences in tumor types and accrual of
adequate numbers for analysis in each group led us to consider them
separately. Similar considerations led to the separate analyses of groups
with BRAF V600E mutations versus other BRAF mutations.
RESULTS
Patients
From April 1, 2014 to November 1, 2016, 251 patients with 35
different tumor types were enrolled from 38 centers in the United
Re-evaluate after every 2 cycles
(6 weeks for pertuzumab plus trastuzumab;
8 weeks for erlotinib, vemurafenib, and vismodegib)
for the first 24 weeks, then every 12 weeks
MyPathway Study
Master protocol with multiple basket studies
Yes
Continue treatment until
progression,
unacceptable toxicity, or
other discontinuation
criteria are met
Disease progression
Objective response
or stable disease
Verify if the patient has
additional mutations
NoDiscontinue treatment
Molecular alterations identified
Treatment
determined after
molecular alteration
confirmed
Mutations
   Well-recognized activating mutations
   Unusual mutations (reported 2 times in COSMIC)
HER2 amplification/overexpression
   IHC3+
   HER2/CEP17 ratio > 2.0
   HER2 gene copy number > 6
Ineligible:
Mutations in which the target
drug is known to be
ineffective (eg, EGFR
mutations in exon 20)
Exclude patients
Tumors with HER2 alterations
(amplification/overexpression or
activating mutation):
trastuzumab (8 mg/kg IV loading
dose, then 6 mg/kg IV every 3 
weeks) plus pertuzumab (840 mg IV 
loading dose, then 420 mg IV every 
3 weeks)
Tumors with
EGFR-activating mutation:
erlotinib 150 mg orally
once daily
Tumors with
BRAF-activating mutation:
vemurafenib 960 mg
orally twice daily
Tumors with alterations in
the Hedgehog pathway
(SMO-activating or PTCH-1
loss-of-function mutation):
vismodegib 150 mg orally
once daily
Eligible:
Fig 1. MyPathway study design. BRAF, murine sarcoma viral (v-raf) oncogene homolog B1; CEP17, centromeric probe for chromosome 17; COSMIC, Catalogue of
Somatic Mutations in Cancer; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor-2; IHC, immunohistochemistry; IV, intravenous;
PTCH-1, patched homolog-1; q3w, every 3 weeks; SMO, smoothened.
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States. The efﬁcacy analysis population includes 230 patients;
the remaining 21 patients had not yet reached the ﬁrst efﬁcacy
evaluation. Patient demographics for the efﬁcacy analysis group
included: median age 62 years (range, 23 to 86 years), 51.0%
male, 91.6% good performance status (Eastern Cooperative
Oncology Group 0 or 1), and a median of 2.5 prior systemic
treatment regimens (range, 0 to 9). In 107 patients, molecular
alterations were detected in tumor tissue obtained at the time of
diagnosis (primary site, n = 66; metastatic site, n = 37; unknown
site, n = 4), whereas 123 patients had alterations detected in
subsequent biopsies. Table 2 lists the tumor types and molecular
alterations.
Tumor molecular alterations identiﬁed in the 230 patients
were as follows: HER2, 151 (66%); BRAF, 49 (21%); Hedgehog, 21
(9%); and EGFR, nine (4%). Of the 151 patients enrolled in the
HER2 arm, 114 exhibited HER2 ampliﬁcation/overexpression (12
of whom also had HER2 mutations), 36 had HER2-activating
mutations (without ampliﬁcation detected by next-generation
sequencing), and one had an RBMS-NRG1 fusion (an alteration
suggested to result in HER2 pathway activation). Twenty-six of the
49 patients with BRAF-mutated tumors had V600E mutations,
whereas 23 patients had tumors with a variety of other BRAF-
activating mutations.
Efficacy
The median duration of follow-up for the efﬁcacy population
was 9.7 months (range, 0.3 to 22.1 months). Fifty-two patients
(23%) with 14 tumor types had objective responses (four complete
responses [CR], 48 partial responses [PR]), and 26 additional
patients had SD for . 120 days. Responses were seen with each of
the four targeted treatments.
Four tumor-pathway cohorts have enrolled at least 12 patients
and had protocol-mandated efﬁcacy review: HER2 ampliﬁed/
overexpressing colorectal cancer (n = 37), HER2 ampliﬁed/
overexpressing NSCLC (n = 16), HER2-mutated NSCLC (n = 14),
and BRAF V600E-mutated NSCLC (n = 14). All four cohorts
exceeded minimum efﬁcacy criteria, and accrual has been ex-
tended. Several other cohorts have shown evidence of activity
but have not reached the size for formal review. No tumor-
pathway cohorts have been closed for lack of efﬁcacy. However,
the study was closed to further accrual of BRAF non-V600
mutations because of the low response rate (one of 23; 4%) in
diverse tumor types.
Patients With HER2 Amplification/Overexpression
Thirty of 114 patients (26%; 95%CI, 19% to 35%) with HER2
ampliﬁcation/overexpression had objective responses to treatment
with trastuzumab plus pertuzumab (two CR, 28 PR). Objective
responses were seen in nine primary tumor types: colorectal,
bladder, biliary, salivary gland, NSCLC, pancreas, ovary, prostate,
and skin (apocrine; Table 3).
Patients with HER2-ampliﬁed/overexpressing metastatic co-
lorectal cancer composed the largest tumor-pathway cohort. In this
group of 37 patients with refractory disease (median, four previous
lines of therapy), treatment with trastuzumab plus pertuzumab
produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A).
An additional four patients had SD. 120 days. The median DOR
was 11 months (range,, 1 to 16+ months; 95% CI, 2.8 months to
not estimable).
Although the other tumor-pathway cohorts are relatively
small, treatment with trastuzumab plus pertuzumab showed
substantial activity in several other refractory tumor types.
Three of nine patients (33%; 95% CI, 8% to 70%) with ad-
vanced bladder cancer had responses (one CR ongoing at
15 months; two PR lasting 1 and 6 months), and two patients
had SD. 120 days (Fig 2B). Two of seven patients (29%; 95% CI,
4% to 71%) with biliary cancer had PR, and three had
SD. 120 days (Fig 2C). Finally, four of ﬁve patients with salivary
gland carcinoma (80%; 95% CI, 28% to . 99%) had responses
(all PR).
Table 2. Tumor Types and Molecular Alterations
Primary Site HER2 BRAF
Hedgehog
Pathway EGFR Total
Lung, non–small-cell 30 21 3 0 54
Colorectal 40 2 0 0 42
Biliary 11* 3 0 1 15
Ovary 8 4 2 0 14
Bladder 13 0 0 0 13
Pancreas 9 4 0 0 13
Uterus 7 0 0 0 7
Breast 2† 0 2 2 6
Salivary gland 5 0 1 0 6
Small intestine 4 0 1 1 6
Prostate 1 3 1 0 5
Unknown primary 1 3 1 0 5
Other (21 tumor types) 20 9 10 5 44
Total 151 (66%) 49 (21%) 21 (9%) 9 (4%) 230
NOTE. N = 230.
Abbreviations: BRAF, murine sarcoma viral (v-raf) oncogene homolog B1;
EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor
receptor-2.
*One patient had a tumor with an RBMS-NRG1 fusion.
†Both had HER2 mutations without ampliﬁcation or overexpression.
Table 3. Efﬁcacy of Treatment With Trastuzumab Plus Pertuzumab in Patients
With HER2 Ampliﬁcation/Overexpression
Primary Site
No. of
Patients
Response, No. (%)
ORR, %
(95% CI)CR PR SD . 120 Days
Colorectal 37 0 14 (38) 4 (11) 38 (23 to 55)
Lung,
non–small-
cell
16 0 2 (13) 2 (13) 13 (2 to 38)
Bladder 9 1 (11) 2 (22) 2 (22) 33 (8 to 70)
Pancreas 9 0 2 (22) 1 (11) 22 (3 to 60)
Biliary 7 0 2 (29) 3 (38) 29 (4 to 71)
Ovary 8 0 1 (13) 0 13 (0 to 53)
Uterus 7 0 0 0 0
Salivary gland 5 0 4 (80) 0 80 (28 to . 99)
Other (11
sites)*
16 1 (6) 1 (6) 3 (19) 13 (2 to 38)
Total 114 2 (2) 28 (25) 16 (14) 26 (19 to 35)
NOTE. N = 114. Includes 12 patients with ampliﬁcation/overexpression plus
mutation.
Abbreviations: CR, complete response; ORR, objective response rate; PR,
partial response; SD, stable disease.
*Responses occurred in patients with adenocarcinomas of the prostate (one)
and skin (apocrine; one).
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Patients With HER2 Mutation
Thirty-six patients received treatment with trastuzumab plus
pertuzumab for tumors with HER2mutations (without ampliﬁcation/
overexpression); four of these patients (11%; 95% CI, 3% to 26%) had
objective responses. Fourteen of the 36 patients with HER2-mutated
tumors hadNSCLC (adenocarcinoma, n = 13; adenosquamous, n = 1);
in this group, three patients (21%; 95% CI, 5% to 51%) had PR and
three had SD. 120 days. Only one of the other 22 patients withHER2-
mutated tumors responded to treatment with pertuzumab plus tras-
tuzumab (biliary cancer).
Patients With BRAF Mutations
Results of treatment with vemurafenib differed markedly in
tumors with BRAF V600 mutations when compared with those
with other BRAF mutations. Of the 26 patients with BRAF V600
mutations (all V600E), objective responses were seen in 12 patients
(46%; 95% CI, 27% to 67%) with six different tumor types (two
CR, 10 PR; Table 4). In contrast, only one of 23 patients (4%; 95%
CI, 0% to 22%) with other non-V600 BRAF mutations had a PR
(pancreas cancer with a CUX1-BRAF fusion). Nonresponding
BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A
(n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V,
G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10
rearrangement, and MACF1- and WASFL-BRAF fusion.
Fourteen patients had refractory BRAF V600E-mutated NSCLC
(adenocarcinoma, n = 13; sarcomatoid, n = 1), composing the largest
tumor-pathway cohort in the BRAF group (Table 4). Six patients
(43%; 95% CI, 18% to 71%) had objective responses (one CR, ﬁve
PR), and two additional patients had SD . 120 days (Fig 2D). The
median DOR was 5 months (range, 4 to 14 months).
All other tumor-pathway cohorts with BRAF V600E muta-
tions were small (four or fewer patients). Assessment of treatment
efﬁcacy in these groups is therefore not yet possible.
Patients With Hedgehog Pathway or EGFR Mutations
Twenty-one patients had mutations in the Hedgehog pathway
(PTCH-1, n = 18; SMO, n = 3). Three patients had PRs to vismodegib
(unknown primary cancer, n = 1; squamous skin cancer, n = 1;
salivary gland cancer, n = 1); all three patients had PTCH-1–mutated
tumors. Various EGFRmutations were present in the tumors of nine
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Fig 2. Waterfall plots of treatment response in patients with human epidermal growth factor receptor-2 (HER2)-ampliﬁed/overexpressing (A) colorectal, (B) bladder, and (C) biliary
cancers, and (D) patients with murine sarcoma viral (v-raf) oncogene homolog B1 (BRAF ) V600E-mutated non–small-cell lung cancer. Three patients with HER2-ampliﬁed/
overexpressing colorectal cancer, one with HER2-ampliﬁed/overexpressing bladder cancer, and three with BRAF V600E-mutated non–small-cell lung cancer were not evaluated for
response and are not included. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease. + indicates treatment is ongoing.
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patients who received erlotinib; one of nine patients (with urethral
adenocarcinoma) achieved a PR.
DISCUSSION
MyPathway was designed to evaluate the efﬁcacy of targeted treat-
ments in tumors harboring activating molecular alterations in the
HER2, BRAF, EGFR, orHedgehog pathways. In 230 patients who have
been treated and evaluated, all four targeted treatments have produced
meaningful responses, and 14 different tumor types outside of current
US Food and Drug Administration (FDA) indications have respon-
ded. Completion of accrual to MyPathway is projected to take an
additional 2 to 3 years. We believe that early publication of the en-
couraging results in several tumor-pathway cohorts will focus at-
tention on these groups and accelerate deﬁnitive investigation. In
addition, suggestions of activity in other small cohorts may guide the
design of additional studies. As a whole, these early results provide
further evidence of the feasibility and potential value of the basket
study design in deﬁning the optimal use of targeted therapies.
Patientswith refractory,metastaticHER2-ampliﬁed/overexpressing
colorectal cancer composed the largest tumor-treatment group in this
study. The incidence of HER2 ampliﬁcation/overexpression is 2% to
6% in advanced colorectal cancer, accounting for approximately
2,000 patients per year in the United States.25-27 In this study, the
37 patients with colorectal cancer treated with trastuzumab plus
pertuzumab had an ORR of 38% (95% CI, 23% to 55%) and
a median DOR of 11 months (95% CI, 3 months to not estimable).
The response rate and DOR in patients with refractory HER2-
ampliﬁed/overexpressing colorectal cancer indicate that HER2 is
an important driver in this malignancy and compare favorably to the
response rates of other drugs recently approved for use in refractory
colorectal cancer.28-30 Dual HER2-targeted therapy was also effective
in the HER2 Ampliﬁcation for Colorectal Cancer Enhanced Strati-
ﬁcation (HERACLES) trial, in which eight of 27 patients with HER2-
ampliﬁed/overexpressing, KRAS wild-type metastatic colon cancer
(30%) had objective responses to treatment with trastuzumab plus
lapatinib.26
Results are also encouraging in other HER2-ampliﬁed/
overexpressing tumor types, including bladder (33% ORR), biliary
tract (29% ORR), and salivary gland (80% ORR). Although salivary
duct carcinomas are rare, HER2 ampliﬁcation/overexpression is
common in these tumors.31,32 HER2 abnormalities in bladder and
biliary cancers occur in 3% to 5% of patients.33,34 New treatment
options are urgently needed in all of these treatment-refractory tumor
types, and enlargement of these treatment groups is important.
Treatment with vemurafenib had notable activity in patients
with refractory BRAF V600E-mutated cancers (46% ORR). In
BRAF V600E-mutated NSCLC, treatment efﬁcacy (43% ORR;
median DOR, 5 months) was similar to results previously reported
in two other basket trials.15,35 In addition to the subsets deﬁned by
EGFR, ALK, and ROS-1 alterations, patients with BRAF V600E-
mutated NSCLC (approximately 2% of NSCLC36) seem to be an
important and targetable NSCLC subset. In contrast, the response
rate for patients with non-V600E BRAF mutations was only 4%,
and accrual of these patients to MyPathway has been discontinued.
The role of basket trials in identifying patient populations for
targeted therapy remains unclear. To date, most basket trials have
reported mixed results, which may be due to the pathways being
targeted, the methods of molecular testing, or the therapeutic agents
being tested. The design of MyPathway maximizes the chance of
success by using CLIA-approved molecular testing readily available
in the clinic and by selecting FDA-approved targeted agents backed
by more than a decade of translational science and clinical expe-
rience. Although not all genetic alterations are equally actionable, the
four FDA-approved targeted therapies evaluated in MyPathway
producedmeaningful responses in patients with various tumor types
involving well-deﬁned driver alterations.
In conclusion, current results from MyPathway demonstrate
potentially clinically meaningful activity for four approved targeted
regimens in multiple tumor types harboring speciﬁc molecular al-
terations. Durable responses were seen in patients with colorectal,
bladder, biliary, and salivary duct cancers with HER2 activation/
overexpression, in patients with NSCLC with BRAF V600E muta-
tions, and in selected patients with PTCH-1/SMO or EGFR alter-
ations. Treatment of additional patients in each of these groups is
ongoing to better deﬁne the activity of these treatments and to
further clarify the importance ofmolecular and histologic subgroups.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: John D. Hainsworth, Mary Beattie
Provision of study materials or patients: John D. Hainsworth, David R.
Spigel
Collection and assembly of data: Bongin Yoo
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
Table 4. Efﬁcacy of Treatment With Vemurafenib in Patients With BRAF
V600E-Mutated Cancers
Primary Site
No. of
Patients
Response, No. (%)
ORR, %
(95% CI)CR PR SD . 120 Days
Lung,
non–small-
cell
14 1 (7) 5 (36) 2 (14) 43 (18 to 71)
Ovary 4 0 2 (50) 1 (25) 50
Colorectal 2 0 1 (50) 0 50
Unknown
primary
1 0 1 (100) 0 100
Thyroid
(anaplastic)
1 1 (100) 0 0 100
Head/neck
(larynx)
1 0 1 (100) 0 100
Other (3 sites) 3 0 0 0 0
Total 26 2 (8) 10 (38) 3 (12) 46 (27 to 67)
NOTE. N = 26.
Abbreviations: CR, complete response; ORR, objective response rate; PR, partial
response; SD, stable disease.
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